AllianceBernstein’s Novo Nordisk NVO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $658K | Sell |
12,937
-7,293
| -36% | -$346K | ﹤0.01% | 2508 |
|
|
2025
Q4 | $1.03M | Sell |
20,230
-507
| -2% | -$25.9K | ﹤0.01% | 2324 |
|
|
2025
Q3 | $1.15M | Sell |
20,737
-141,897
| -87% | -$8.31M | ﹤0.01% | 2279 |
|
|
2025
Q2 | $11.2M | Buy |
162,634
+139,963
| +617% | +$9.52M | ﹤0.01% | 1125 |
|
|
2025
Q1 | $1.57M | Sell |
22,671
-343
| -1% | -$28.3K | ﹤0.01% | 2022 |
|
|
2024
Q4 | $1.98M | Sell |
23,014
-476
| -2% | -$51.5K | ﹤0.01% | 1962 |
|
|
2024
Q3 | $2.8M | Sell |
23,490
-34,532
| -60% | -$4.61M | ﹤0.01% | 1796 |
|
|
2024
Q2 | $8.28M | Buy |
58,022
+18,360
| +46% | +$2.43M | ﹤0.01% | 1266 |
|
|
2024
Q1 | $5.09M | Buy |
39,662
+5,072
| +15% | +$604K | ﹤0.01% | 1456 |
|
|
2023
Q4 | $3.58M | Buy |
34,590
+6,134
| +22% | +$607K | ﹤0.01% | 1643 |
|
|
2023
Q3 | $2.59M | Sell |
28,456
-89,052
| -76% | -$7.84M | ﹤0.01% | 1741 |
|
|
2023
Q2 | $9.51M | Buy |
117,508
+91,178
| +346% | +$7.45M | ﹤0.01% | 1149 |
|
|
2023
Q1 | $2.1M | Sell |
26,330
-1,104
| -4% | -$78.3K | ﹤0.01% | 1840 |
|
|
2022
Q4 | $1.86M | Sell |
27,434
-482
| -2% | -$28.3K | ﹤0.01% | 1957 |
|
|
2022
Q3 | $1.39M | Buy |
27,916
+500
| +2% | +$26.8K | ﹤0.01% | 2116 |
|
|
2022
Q2 | $1.53M | Buy |
27,416
+318
| +1% | +$17.6K | ﹤0.01% | 2116 |
|
|
2022
Q1 | $1.5M | Sell |
27,098
-14,376
| -35% | -$738K | ﹤0.01% | 2244 |
|
|
2021
Q4 | $2.32M | Sell |
41,474
-83,254
| -67% | -$4.51M | ﹤0.01% | 2047 |
|
|
2021
Q3 | $5.99M | Buy |
124,728
+68,210
| +121% | +$3.3M | ﹤0.01% | 1511 |
|
|
2021
Q2 | $2.37M | Sell |
56,518
-209,334
| -79% | -$8.11M | ﹤0.01% | 2097 |
|
|
2021
Q1 | $8.96M | Buy |
265,852
+83,070
| +45% | +$2.96M | ﹤0.01% | 1258 |
|
|
2020
Q4 | $6.38M | Sell |
182,782
-228,716
| -56% | -$7.91M | ﹤0.01% | 1360 |
|
|
2020
Q3 | $14.3M | Sell |
411,498
-747,304
| -64% | -$24.9M | 0.01% | 908 |
|
|
2020
Q2 | $37.9M | Sell |
1,158,802
-2,531,304
| -69% | -$80.8M | 0.02% | 597 |
|
|
2020
Q1 | $111M | Sell |
3,690,106
-664,332
| -15% | -$19.8M | 0.08% | 226 |
|
|
2019
Q4 | $126M | Sell |
4,354,438
-165,328
| -4% | -$4.58M | 0.07% | 265 |
|
|
2019
Q3 | $117M | Sell |
4,519,766
-1,966,258
| -30% | -$49.7M | 0.07% | 263 |
|
|
2019
Q2 | $166M | Buy |
6,486,024
+3,838,702
| +145% | +$94.9M | 0.1% | 180 |
|
|
2019
Q1 | $69.2M | Sell |
2,647,322
-47,220
| -2% | -$1.16M | 0.05% | 422 |
|
|
2018
Q4 | $62.1M | Sell |
2,694,542
-300,878
| -10% | -$6.69M | 0.05% | 399 |
|
|
2018
Q3 | $70.6M | Buy |
+2,995,420
| New | +$73.1M | 0.05% | 408 |
|
|
2018
Q2 | – | Sell |
-180,226
| Closed | -$4.44M | – | 3134 |
|
|
2018
Q1 | $4.44M | Buy |
180,226
+75,952
| +73% | +$1.99M | ﹤0.01% | 1284 |
|
|
2017
Q4 | $2.8M | Buy |
+104,274
| New | +$2.65M | ﹤0.01% | 1617 |
|
|
2014
Q3 | – | Sell |
-400
| Closed | -$9K | – | 3446 |
|
|
2014
Q2 | $9K | Sell |
400
-50
| -11% | -$1.1K | ﹤0.01% | 3322 |
|
|
2014
Q1 | $10K | Buy |
+450
| New | +$9.59K | ﹤0.01% | 3270 |
|
|
2013
Q3 | – | Sell |
-210
| Closed | -$3K | – | 3490 |
|
|
2013
Q2 | $3K | Buy |
+210
| New | +$3.5K | ﹤0.01% | 3208 |
|
Other funds holding NVO
DAM
F
AllianceBernstein's NVO Position: Q1 2026 in Review
AllianceBernstein reduced its Novo Nordisk (NVO) stake by 36% in Q1 2026, selling an estimated $346K and leaving 12,937 shares worth $658K. The position accounts for ﹤0.01% of the portfolio, ranked #2508.
AllianceBernstein first reported a position in NVO in Q2 2013 and has held it in 36 quarters since. The position peaked at $166M in Q2 2019. 1,271 funds tracked by Wall St. Rank hold NVO as of Q1 2026.
- AllianceBernstein held 12,937 shares of Novo Nordisk worth $658K as of Q1 2026.
- AllianceBernstein sold 7,293 Novo Nordisk shares in Q1 2026, an estimated $346K.
- Novo Nordisk made up ﹤0.01% of AllianceBernstein's portfolio in Q1 2026, its #2508 holding.
- AllianceBernstein first reported a position in Novo Nordisk in Q2 2013 and has held it in 36 quarters since.
- AllianceBernstein's Novo Nordisk position peaked at $166M in Q2 2019.
- 1,271 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.
Based on AllianceBernstein's 13F filing for Q1 2026, filed 15 May 2026.